Weekly Digest – April 2024 Weekly Digest – April 2024 8 Apr 2024: Genmab to acquire ADC maker ProfoundBio Genmab to acquire ProfoundBio for $1.8 billion Acquisition includes three clinical-stage drug candidates: Rinatabart sesutecan targets folate receptor α in ovarian […]
Weekly Digest – April 2024 Weekly Digest – April 2024 4 Apr 2024: Caris Life Sciences partners with Merck KGaA to discover cancer targets and fast-track ADC development Caris Life Sciences partners with Merck KGaA to accelerate ADC development for […]
Weekly Digest – April 2024 Weekly Digest – April 2024 2 Apr 2024: Ipsen licenses Sutro ADC in $900m deal Ipsen expands oncology pipeline through a licensing agreement with Sutro Biopharma for STRO-003, an ADC targeting ROR1 ROR1 is a […]
Weekly Digest – April 2024 Weekly Digest – April 2024 2 Apr 2024: Datopotamab deruxtecan BLA accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer AstraZeneca and Daiichi Sankyo’s BLA for Datopotamab deruxtecan in HR-positive, […]
Weekly Digest – April 2024 Weekly Digest – April 2024 1 Apr 2024: Adcentrx Therapeutics to showcase Preclinical findings of Nectin-4 ADC Program at AACR Annual Meeting 2024 Adcentrx Therapeutics will present preclinical data for ADRX-0706 at AACR Annual Meeting […]
